ArticlePloS one2021
Prevalence and incidence of neuromuscular conditions in the UK between 2000 and 2019: A retrospective study using primary care data.
Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Prevalence, Incidence, and Mortality of Myasthenia Gravis and Myasthenic Syndromes: A Systematic Review.Neuroepidemiology · 2025Pooled it
- Variation in worldwide incidence of Guillain-Barré syndrome: a population-based study in urban China and existing global evidence.Frontiers in immunology · 2024Pooled it
- A meta-analysis on the prevalence of Charcot-Marie-Tooth disease and related inherited peripheral neuropathies.Journal of neurology · 2023Pooled it
- The epidemiology of inflammatory rheumatic diseases in Germany in a European context: a systematic review to support workforce planning.EULAR rheumatology open · 2026Article
- Myasthenia Gravis (MG) Resource Utilization, Epidemiology, Survival, and Treatment Patterns (MG-REST): Estimating the Clinical and Economic Burden in Ontario, Canada.European journal of neurology · 2026Article
- 2nd NMD4C basic research summer school on promoting standardized protocols to advance translational research in neuromuscular disorders.Journal of neuromuscular diseases · 2026Article
- Systematic mapping of rare genetic disease studies using UK primary care electronic health records.European journal of human genetics : EJHG · 2026Review
- Myasthenia gravis following the initiation of statin therapy: A multinational self-controlled case series study.Journal of internal medicine · 2026Observational
- Charcot-Marie-Tooth disease and related neuropathies.Nature reviews. Disease primers · 2026Review
- Deep Learning outperforms physicians in myopathy and neuropathy classification based on Needle Electromyography Signal.PloS one · 2026Article
- The incidence and mortality of connective tissue diseases: a population-level cohort study in England from 2012 to 2023.Rheumatology (Oxford, England) · 2025Article
- Inherited Peripheral Neuropathies.Neurologic clinics · 2025Review
- Prevalence and incidence rates of 17 neuromuscular disorders: An updated review of the literature.Journal of neuromuscular diseases · 2025Review
- The Leeds Motor Neuron Disease Percutaneous Endoscopic Gastrostomy Pathway: Improving Clinical Outcomes and Experience in a UK Center.Neurology. Clinical practice · 2025Article
- Evaluation of the impact of defining observable time in real-world data on outcome incidence.Journal of the American Medical Informatics Association : JAMIA · 2025Article
- Wearable devices in neurological disorders: a narrative review of status quo and perspectives.Annals of translational medicine · 2025Review
- Epidemiological report and diagnostic approach used in the neuromuscular population of Liege, Belgium.Orphanet journal of rare diseases · 2025Article
- Assessing the socio-economic burden of inherited and inflammatory neuromuscular diseases (BIND study): a study protocol.Orphanet journal of rare diseases · 2025Article
- Incidence and Prevalence of Juvenile Myasthenia Gravis in the United States Between 2010 and 2020: Analysis of Two Claims Databases.Neurology and therapy · 2025Article
- Estimating the Prevalence of Autosomal Recessive Neuromuscular Diseases in the Korean Population.Journal of Korean medical science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn the UK, large-scale electronic primary care datasets can provide up-to-date, accurate epidemiological information on rarer diseases, where specialist diagnoses from hospital discharges and clinic letters are generally well recorded and electronically searchable. Current estimates of the number of people living with neuromuscular disease (NMD) have largely been based on secondary care data sources and lacked direct denominators.
objectiveTo estimate trends in the recording of neuromuscular disease in UK primary care between 2000-2019.
methodsThe Clinical Practice Research Datalink (CPRD) database was searched electronically to estimate incidence and prevalence rates (per 100,000) for a range of NMDs in each year. To compare trends over time, rates were age standardised to the most recent CPRD population (2019).
resultsApproximately 13 million patients were actively registered in each year. By 2019, 28,230 active patients had ever received a NMD diagnosis (223.6), which was higher among males (239.0) than females (208.3). The most common classifications were Guillain-Barre syndrome (40.1), myasthenia gravis (33.7), muscular dystrophy (29.5), Charcot-Marie-Tooth (29.5) and inflammatory myopathies (25.0). Since 2000, overall prevalence grew by 63%, with the largest increases seen at older ages (≥65-years). However, overall incidence remained constant, though myasthenia gravis incidence has risen steadily since 2008, while new cases of muscular dystrophy fell over the same period.
conclusionsLifetime recording of many NMDs on primary care records exceed current estimates of people living with these conditions; these are important data for health service and care planning. Temporal trends suggest this number is steadily increasing, and while this may partially be due to better recording, it cannot be simply explained by new cases, as incidence remained constant. The increase in prevalence among older ages suggests increases in life expectancy among those living with NMDs may have occurred.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.